Overview
- The six‑year‑old patient known as Mei died after receiving a bespoke CRISPR base‑editing treatment delivered by two viral vectors into her spinal fluid, a procedure performed in March 2025 that investigators say produced a severe immune reaction.
- Science and Retraction Watch reported that the lead researcher, Zilong Qiu, did not disclose the death and removed the family’s genetic sequences and an acknowledgement of their more than $800,000 in funding from a Nature manuscript before publication.
- Shanghai Jiao Tong University School of Medicine has opened a formal investigation into Qiu’s conduct and non‑disclosure, and outside scientists and ethicists have urged Nature to review the published paper and its underlying data.
- A local health authority fined the hospital about $3,600 for supervision failures, a penalty critics call minimal amid questions about informed consent, payment to researchers, and the ethics of asking families to fund first‑in‑human trials.
- Industry figures warn the episode exposes gaps in risk assessment and transparency that could trigger stricter rules for investigator‑initiated trials in China and slow the rapid development pathway that has driven recent biotech advances.